The positive results from the Phase 1 study of ACU193 for early Alzheimer's disease presented by Acumen Pharmaceuticals at the Alzheimer's Association International Conference 2023 have led to an increase in the company's stock prices. This is because positive clinical trial results often lead to increased investor confidence in a company's potential for future success, which can drive up its stock prices.